Evidence map›Paper›PMID 38219917›Full record

ArticleThe Journal of investigative dermatology2024

Romidepsin and Afatinib Abrogate Jak-Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma.

Bobby B Shih, Cindy Ma, Jose R Cortes, Clara Reglero, Hannah Miller, S Aidan Quinn, Robert Albero, Anouchka P Laurent, Adam Mackey, Adolfo A Ferrando and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Epigenetic dysregulation in mycosis fungoides and sézary syndrome.Frontiers in cell and developmental biology · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Bobby B ShihInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
Cindy MaInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
Jose R CortesInstitute for Cancer Genetics, Columbia University, New York, New York, USA; Regeneron Pharmaceuticals, Tarrytown, New York, USA.
Clara RegleroInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
Hannah MillerInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
S Aidan QuinnInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
Robert AlberoInstitute for Cancer Genetics, Columbia University, New York, New York, USA; Biomedical Research Institute August Pi y Sunyer (IDIBAPS), Barcelona, Spain.
Anouchka P LaurentInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
Adam MackeyInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
Adolfo A FerrandoInstitute for Cancer Genetics, Columbia University, New York, New York, USA; Regeneron Pharmaceuticals, Tarrytown, New York, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA; Department of Pediatrics, Columbia University Medical Center, New York, New York, USA; Department of Systems Biology, Columbia University Medical Center, New York, New York, USA.
Larisa GeskinDepartment of Medicine, Columbia University Medical Center, New York, New York, USA.
Teresa PalomeroInstitute for Cancer Genetics, Columbia University, New York, New York, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA. Electronic address: tp2151@cumc.columbia.edu.
Cancer Genetics (United States) · USColumbia University Irving Medical Center · USRegeneron (United States) · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Single-cell characterization of tumor and microenvironment co-evolution in Peripheral T-cell LymphomasU01CA243073 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PALOMERO, TERESA, RABADAN, RAUL · 2019 to 2023
$3.0M
Role and Mechanisms of VAV1 alterations in Peripheral T-cell LymphomasR01CA256341 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PALOMERO, TERESA · 2021 to 2025
$1.8M
Mechanism of Transformation in T-Cell Lymphomas: Identification of Therapeutic TargetsF31CA261153 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHIH, BOBBY BEN · 2021 to 2023
$137k
NCI NIH HHS F31 CA261153NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA256341NCI NIH HHS U01 CA243073
6 · The paper itself

Abstract

Cutaneous T-cell lymphomas are mature lymphoid neoplasias resulting from the malignant transformation of skin-resident T-cells. A distinctive clinical feature of cutaneous T-cell lymphomas is their sensitivity to treatment with histone deacetylase inhibitors. However, responses to histone deacetylase inhibitor therapy are universally transient and noncurative, highlighting the need for effective and durable drug combinations. In this study, we demonstrate that the combination of romidepsin, a selective class I histone deacetylase inhibitor, with afatinib, an EGFR family inhibitor, induces strongly synergistic antitumor effects in cutaneous T-cell lymphoma models in vitro and in vivo through abrogation of Jak-signal transducer and activator of transcription signaling. These results support a previously unrecognized potential role for histone deacetylase inhibitor plus afatinib combination in the treatment of cutaneous T-cell lymphomas.

Indexed as

AfatinibDepsipeptidesDrug SynergismLymphoma, T-Cell, CutaneousSignal TransductionSkin NeoplasmsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorHistone Deacetylase InhibitorsHumansJanus KinasesMiceXenograft Model Antitumor AssaysAfatinibDepsipeptidesHistone Deacetylase InhibitorsJanus KinasesromidepsinCombination therapyCutaneous T-cell lymphomaPreclinical modelsRomidepsin

Identifiers

PMID38219917
PMCPMC11193653
OpenAlexW4390889518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.